A major international study published in Nature Medicine reveals that a new liquid biopsy test, PANXEON, can detect early‑stage pancreatic cancer with high sensitivity and a low false‑positive rate. The test successfully identifies stages 1 and 2 cancers, offering hope for earlier diagnosis and improved survival in a disease often detected too late.
About the Author
